Gennex Laboratories Limited (531739) Fair Value & Analysis
Healthcare · IN · Market cap ₹473M
Fair value as of: Jul 4, 2026
From 14 valuation models · updated today
Share price −8.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹7.13 – ₹17.02 · fair‑value band ₹21.14 – ₹35.24 · the ₹10.16 price screens below the ₹28.19 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gennex Laboratories Limited (531739) currently trades at ₹10.16, while our model-based Fair Value estimate is ₹28.19 — implying the stock looks roughly 177.5% undervalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Gennex Laboratories Limited generated revenue of ₹530M at a net margin of 2.7%. Revenue declined 19.7% year over year. Net debt stands at ₹793M. The stock trades on a trailing P/E of 32.2. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole. Its pipeline products include Melitracen Hydrochloride; Flupentixol Di-Hydrochloride; Domperidone; Potassium Guaiacol Sulphonate; Mefenamic Acid; Melitracen; and Chlorphenesin. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Gennex Laboratories Limited reported revenue of ₹1.7B in FY2026 versus ₹612M in FY2022, a compound +29.6%/yr. Reported net income was ₹210M in FY2026, compounding +52.1%/yr from FY2022.
Is 531739 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹244.55 | ₹96.79 | -60% |
| Anuh Pharma Limited 506260 | ₹80.21 | ₹110.37 | +38% |
| Medicamen Biotech Limited 531146 | ₹262.00 | ₹98.91 | -62% |
| Coral Laboratories Limited 524506 | ₹605.55 | ₹779.49 | +29% |
| Lactose (India) Limited 524202 | ₹103.75 | ₹130.91 | +26% |
| Beryl Drugs Limited 524606 | ₹21.22 | ₹17.12 | -19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gennex Laboratories Limited (531739) undervalued?
What is the fair value of 531739?
What is the quality score of 531739?
What is the revenue of Gennex Laboratories Limited (531739)?
What is the net profit margin of 531739?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.